MenaQ7 Metabolic combines two key active ingredients, MenaQ7 Vitamin K2 as MK-7 and ANKASCIN 568-R, extracted from the fermentation product of Monascus purpureus NTU 568, a patented functional red yeast strain. Masu.
“This innovative formula not only addresses the root causes of metabolic problems, but also provides a holistic approach to maintaining heart health, bone strength, and optimal metabolic function. MenaQ7 and ANKASCIN 568 The extensive clinical research behind both -R supports the effectiveness of this unique blend, making it a vital choice for those looking to improve their cardiometabolic health.”Mr. John Pan, general manager of Sunway Biotech, said:
Growing demand for vitamin K2 and red yeast rice extract
Pang noticed that people in the Asia-Pacific region in particular prefer richer, more flavorful foods. If such a diet is high in sugar and fat, it may increase the risk of metabolic syndrome.
He believes this is the main driver of the increased demand for cardiometabolic health supplements containing vitamin K2 and red yeast rice extract.
Pan points out that the vitamin K2 market is expected to grow at a CAGR of 10-15% from 2021 to 2025. This upward trend is driven by the increasing demand for vitamin K2-enriched products, as evidenced by sales growth of over 30%. Since 2015, we have seen an increase in product launches.
The Red Yeast Supplements market size was valued at $525.9 million in 2022 and is expected to grow at a CAGR of 8.04% from 2023 to 2030, and reach $972.4 million by 2030.
“The partnership between SunWay Biotech and Gnosis by Lesaffre to launch MenaQ7® Metabolic highlights the dynamic growth of this sector by providing a synthetic chemical-free solution for cardiovascular health. This resonates with growing consumer demand for safer and more natural health solutions.”Pan said.
Science-backed solutions to cardiometabolic problems
Vitamin K2 is found in chickpeas and natto, a traditional Japanese food. It is essential for both bone and cardiovascular health by activating the proteins that bind calcium to bones, increasing bone density and reducing fracture risk. Additionally, it helps maintain heart health by preventing arterial calcification and keeping arteries flexible.
Human clinical studies have demonstrated the health benefits associated with MenaQ7 Vitamin K. In particular, menaquinone-7 supplementation improves arterial stiffness and helps reduce bone loss in healthy postmenopausal women. It has also been shown to have a positive effect on body fat and weight.
Red yeast rice is a traditional herbal medicine and dietary supplement popular in East Asian countries such as China, Japan, Korea, and Thailand. Traditional red yeast supplements contain naturally occurring monacolin K, which is well known for lowering cholesterol and triglyceride levels and improving blood circulation in humans. However, monacolin K can cause the same side effects as statin drugs, including muscle, kidney, and liver damage.
ANKASCIN® 568-R, on the other hand, is the only fermented botanical ingredient that does not contain monacolin K.
Sunway Biotech has completed 5 clinical trials and over 130 SCI publications for ANKASCIN® 568-R, demonstrating its effectiveness in blood sugar levels, lipid profile, blood pressure maintenance, cognitive function, and weight management. is shown.
ANKASCIN® 568-R also contains two key pigments derived from red yeast rice, monascin and ankaflavin. These ingredients have stronger effects than traditional red yeast rice and have no side effects. For example, it addresses the root causes of aging-related factors such as advanced glycation end products (AGEs) and inflammatory cytokines. It also helps with blood sugar management, cardiovascular health, weight management, and cognitive health.
Therefore, the combination of MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R represents a unique complementary approach to cardiometabolic health.
distribution plan
SunWay Biotech and Gnosis by Lesaffre aim to expand globally by leveraging this partnership to tackle some of the world’s most prevalent health issues.
They plan to first introduce MenaQ7® Metabolic to Taiwan, a market open to innovative health solutions. Subsequently, the company plans to expand into China and Malaysia to capitalize on the growing demand for high-quality health supplements in the region.
This phased approach allows us to tailor our launch strategy to each market’s unique preferences and regulatory situation, ensuring a solid foundation for broader Asian expansion.
Healthy product innovation will take center stage at Growth Asia Summit 2024 next July, featuring insights from a wide range of industry leaders and experts. Don’t miss out – register here now!
